Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Target

Compare

4,221 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RXRX Analyst Ratings

Moderate Buy

2 Buy

4 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Recursion

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RXRX Stock 12 Month Forecast

Average Price Target

$7.75

▲(65.60% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Recursion Pharmaceuticals in the last 3 months. The average price target is $7.75 with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 65.60% change from the last price of $4.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","12":"$12","5.25":"$5.25","7.5":"$7.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.25,7.5,9.75,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.36,4.870769230769231,5.381538461538462,5.892307692307693,6.403076923076924,6.913846153846154,7.424615384615385,7.935384615384615,8.446153846153846,8.956923076923077,9.467692307692307,9.978461538461538,10.489230769230769,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.36,4.620769230769231,4.881538461538462,5.142307692307693,5.403076923076924,5.663846153846154,5.924615384615385,6.185384615384615,6.446153846153846,6.706923076923077,6.967692307692308,7.228461538461539,7.489230769230769,{"y":7.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.36,4.40923076923077,4.458461538461539,4.507692307692308,4.556923076923077,4.6061538461538465,4.655384615384616,4.704615384615384,4.753846153846154,4.803076923076923,4.852307692307693,4.901538461538461,4.950769230769231,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.58,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.24,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.51,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.68,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$11.00

Average Price Target$7.75

Lowest Price Target$5.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Priyanka Grover

J.P. Morgan

$10→$11

Buy

135.04%

Upside

Upgraded

12/17/25

Analysts Are Bullish on These Healthcare Stocks: Novan (NOVN), Recursion Pharmaceuticals (RXRX)

Sean Laaman

Morgan Stanley

Hold

6.84%

Upside

Reiterated

12/08/25

Cautious Optimism for Recursion Pharmaceuticals: Promising TUPELO Study Results Lead to Hold Rating

Gil Blum

Needham

Buy

70.94%

Upside

Reiterated

12/08/25

Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals

Alec Stranahan

Bank of America Securities

Hold

49.57%

Upside

Reiterated

12/08/25

Cautious Hold Rating on Recursion Pharmaceuticals Amid Promising REC-4881 Data and Safety Concerns

Brendan Smith

TD Cowen

Hold

―

Reiterated

11/05/25

Recursion Pharmaceuticals: Advancements and Leadership Transition Lead to Hold Rating

Mani Foroohar

Leerink Partners

Hold

―

Reiterated

10/15/25

Scott Schoenhaus

KeyBanc

$12→$10

Buy

113.68%

Upside

Reiterated

01/08/25

Recursion Pharmaceuticals price target lowered to $10 from $12 at KeyBancRecursion Pharmaceuticals price target lowered to $10 from $12 at KeyBanc

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Priyanka Grover

J.P. Morgan

$10→$11

Buy

135.04%

Upside

Upgraded

12/17/25

Analysts Are Bullish on These Healthcare Stocks: Novan (NOVN), Recursion Pharmaceuticals (RXRX)

Sean Laaman

Morgan Stanley

Hold

6.84%

Upside

Reiterated

12/08/25

Cautious Optimism for Recursion Pharmaceuticals: Promising TUPELO Study Results Lead to Hold Rating

Gil Blum

Needham

Buy

70.94%

Upside

Reiterated

12/08/25

Promising Clinical Study Results and FDA Meeting Propel Buy Rating for Recursion Pharmaceuticals

Alec Stranahan

Bank of America Securities

Hold

49.57%

Upside

Reiterated

12/08/25

Cautious Hold Rating on Recursion Pharmaceuticals Amid Promising REC-4881 Data and Safety Concerns

Brendan Smith

TD Cowen

Hold

―

Reiterated

11/05/25

Recursion Pharmaceuticals: Advancements and Leadership Transition Lead to Hold Rating

Mani Foroohar

Leerink Partners

Hold

―

Reiterated

10/15/25

Scott Schoenhaus

KeyBanc

$12→$10

Buy

113.68%

Upside

Reiterated

01/08/25

Recursion Pharmaceuticals price target lowered to $10 from $12 at KeyBancRecursion Pharmaceuticals price target lowered to $10 from $12 at KeyBanc

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Recursion Pharmaceuticals

1 Month

xxx

Success Rate

8/23 ratings generated profit

Average Return

+0.57%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 34.78% of your transactions generating a profit, with an average return of +0.57% per trade.

3 Months

xxx

Success Rate

11/23 ratings generated profit

Average Return

+6.86%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.83% of your transactions generating a profit, with an average return of +6.86% per trade.

1 Year

Gil BlumNeedham

Success Rate

6/23 ratings generated profit

Average Return

-12.68%

reiterated a buy rating 11 days ago

Copying Gil Blum's trades and holding each position for 1 Year would result in 26.09% of your transactions generating a profit, with an average return of -12.68% per trade.

2 Years

xxx

Success Rate

2/23 ratings generated profit

Average Return

-26.05%

reiterated a xxx

rating 11 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 8.70% of your transactions generating a profit, with an average return of -26.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RXRX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RXRX has received 3 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. RXRX average Analyst price target in the past 3 months is 7.75.

Each month's total comprises the sum of three months' worth of ratings.

RXRX Financial Forecast

RXRX Earnings Forecast

Next quarter’s earnings estimate for RXRX is -$0.31 with a range of -$0.46 to -$0.21. The previous quarter’s EPS was -$0.36. RXRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year RXRX has Performed in-line its overall industry.

RXRX Sales Forecast

Next quarter’s sales forecast for RXRX is $24.54M with a range of $17.10M to $46.10M. The previous quarter’s sales results were $5.17M. RXRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year RXRX has Performed in-line its overall industry.

RXRX Stock Forecast FAQ

What is RXRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Recursion Pharmaceuticals’s 12-month average price target is 7.75.

What is RXRX’s upside potential, based on the analysts’ average price target?

Recursion Pharmaceuticals has 65.60% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RXRX a Buy, Sell or Hold?

Recursion Pharmaceuticals has a consensus rating of Moderate Buy which is based on 2 buy ratings, 4 hold ratings and 0 sell ratings.

What is Recursion Pharmaceuticals’s price target?

The average price target for Recursion Pharmaceuticals is 7.75. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $11.00 ,the lowest forecast is $5.00. The average price target represents 65.60% Increase from the current price of $4.68.

What do analysts say about Recursion Pharmaceuticals?

Recursion Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of RXRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Target

RXRX Analyst Ratings

RXRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Recursion Pharmaceuticals

RXRX Analyst Recommendation Trends

RXRX Financial Forecast

RXRX Earnings Forecast

RXRX Sales Forecast

RXRX Stock Forecast FAQ

Detailed List of Analyst Forecasts